Citations

Clear

1575 citation(s) found for "Im, Gene".

A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy
Sebastian, Nikhil , Xu‐Welliver, Meng , Haglund, Karl, Brownstein, Jeremy , DeNicola, Gina M. , Sebastian, Nikhil T , Xu-Welliver, Meng, Webb, Amy , Shilo, Konstantin , Robb, Ryan N. , Shen, Changxian , Williams, Terence M.

Mayo Clinic

Cancer | August 10, 2023 | Volume: 129 | Issue: 24 | Pages: 3971-3977

10.1002/cncr.34983 | PMID 37560930 Get It

AbstractIntroductionIncreasingly, early‐stage non–small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT). Although treatment is generally effective, a small subset of tumors will recur because of radioresistance. Preclinical studies suggested PI3K‐AKT‐mTOR activation mediates radioresistance. This study sought to validate this finding in tumor samples from patients who underwent SBRT for NSCLC.MethodsPatients with T1‐3N0 NSCLC treated with SBRT at our institution were included. Total RNA of formalin‐fixed paraffin‐embedded tumor biopsy specimens (pretherapy) was isolated and analyzed using the Clariom D assay. Risk scores from a PI3K activity signature and four published NSCLC signatures were generated and dichotomized by the median. Kaplan–Meier curves and Cox regressions were used to analyze their association with recurrence and overall survival (OS). The PI3K signature was also tested in a data set of resected NSCLC for additional validation.ResultsA total of 92 patients were included, with a median follow‐up of 18.3 months for living patients. There was no association of any of the four published gene expression signatures with recurrence or OS. However, high PI3K risk score was associated with higher local recurrence (hazard ratio [HR], 11.72; 95% CI, 1.40–98.0; p = .023) and worse disease‐free survival (DFS) (HR, 3.98; 95% CI, 1.57–10.09; p = .0035), but not OS (p = .49), regional recurrence (p = .15), or distant recurrence (p = .85). In the resected NSCLC data set (n = 361), high PI3K risk score was associated with decreased OS (log‐rank p = .013) but not DFS (p = 0.54).ConclusionsThis study validates that higher PI3K activity, measured by gene expression, is associated with local recurrence and worse DFS in early‐stage NSCLC patients treated with SBRT. This may be useful in prognostication and/or tailoring treatment, and merits further validation.
A RANDOMIZED CONTROLLED TRIAL OF KINEMATICALLY AND MECHANICALLY ALIGNED TOTAL KNEE ARTHROPLASTY: 12-YEAR FOLLOW-UP
Arthur, Jameson, Makovicka, Justin L. , Dossett, H. Gene , Bingham, Joshua S. , Spangehl, Mark J. , Clarke, Henry D.

Mayo Clinic

Orthopaedic Proceedings | August 7, 2023 | Volume: 105-B | Issue: SUPP_13 | Pages: 53-53

10.1302/1358-992x.2023.13.053 Get It

AbstractIntroductionThe optimal alignment technique for total knee replacement (TKR) remains controversial. We previously reported six-month and two-year results of a randomized controlled trial comparing kinematically (KA) versus mechanically (MA) aligned TKR. In the present study, we report 12-year results from this trial.MethodsThe original cohort included 88 TKRs (44 KA using Shape Match patient-specific guides and 44 MA using conventional instrumentation), performed from 2008 to 2009. After IRB approval, the health record of the original 88 patients were queried. Revisions, re-operations, and complications were recorded. The non-deceased patients were contacted via phone. Reoperation and complications were documented via the patient's history. Further, a battery of patient-reported outcome measures (including patient satisfaction, WOMAC, Oxford, KOOS Jr, Forgotten Joint Score, and M-SANE) were obtained.ResultsOf the original 88 patients in the study, 15 patients had a least one reoperation (17%). Patella problems were the most common cause of reoperation accounting for 5/8 reoperations in the KA group versus 3/7 in the MA group. There was no statistically significant difference between the two alignment methods in terms of major and minor complications or reoperations. At the 12-year follow-up, 26 patients died leaving 62 patients for follow-up. Of these, 48 patients (77%) were successfully contacted. The kinematically aligned total knees self-reported better satisfaction (96% versus 82%), but no difference in other patient-reported outcome measures compared to mechanically aligned TKRs.ConclusionKA TKR demonstrates excellent mid to long-term results compared to MA TKR with similar reoperations, complications, and patient-reported outcome measures.
RNA Sequencing for Solid Tumor Fusion Gene Detection: Proficiency Testing Practice and Performance Comparison
Bridge, Julia A. , Halling, Kevin C. , Moncur, Joel T., Souers, Rhona J., Fernandes, Helen , Roy, Angshumoy , Surrey, Lea F. , Tafe, Laura J. , Vasalos, Patricia, López‐Terrada, Dolores , Hameed, Meera

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 3, 2023 | Volume: 148 | Issue: 5 | Pages: 538-544

10.5858/arpa.2023-0047-cp | PMID 37535666 Get It

Context Next-generation sequencing–based approaches using RNA have increasingly been used by clinical laboratories for the detection of fusion genes, intragenic rearrangements, and exon-skipping events. Correspondingly, the College of American Pathologists (CAP) has advanced RNA sequencing proficiency testing (PT) to ensure optimal performance of these assays. Objective To report on laboratory performance and practices of RNA sequencing for the detection of fusion genes, intragenic rearrangements, and exon-skipping events using CAP PT data from 8 mailings (2018-A through 2021-B). Design CAP PT RNA sequencing program results from 153 laboratories across 24 proficiency test specimens, interrogating 22 distinct engineered fusion transcripts, were analyzed for correct identification of the fusion event, associated performance variables, and laboratory practices. Results Overall, the 4-year program detection rate (sensitivity) was 95.5% (1486 of 1556 results). False-negative rates were 3.6% (53 of 1463) and 18.3% (17 of 93) for fusion gene and intragenic rearrangement/exon-skipping events, respectively. Only 19 false-positive results were reported among the 8 PT mailings, and most were likely the result of preanalytical or postanalytical errors. There were no practice characteristics (eg, instrumentation, sequencing method) significantly associated with the fusion detection results. Conclusions These data reveal a high overall sensitivity and specificity for fusion gene detection by participating laboratories using clinical RNA sequencing. Performance was comparable across all laboratories, regardless of methodology. The fraction of false-negative results for intragenic rearrangement/exon-skipping events was greater than that for the chimeric fusion genes. False-negative results could not be attributed to any specific practice characteristics.
Unilateral Relapsing Primary CNS Vasculitis
Hunder, Gene G. , Huston, John , Brown, Robert D. , Huston, John , Salvarani, Carlo , Giannini, Caterina

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | August 2, 2023 | Volume: 10 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000200142 | PMID 37532518 Get It

Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease
Herdt, Aimee, Peng, Hui , Dickson, Dennis W. , Golde, Todd E. , Eckman, Elizabeth A. , Lee, Chris W. , Dickson, Dennis W

Mayo Clinic

Genes | July 26, 2023 | Volume: 14 | Issue: 8 | Pages: 1517

10.3390/genes14081517 | PMID 37628569 Get It

Krabbe disease (KD) is a progressive and devasting neurological disorder that leads to the toxic accumulation of psychosine in the white matter of the central nervous system (CNS). The condition is inherited via biallelic, loss-of-function mutations in the galactosylceramidase (GALC) gene. To rescue GALC gene function in the CNS of the twitcher mouse model of KD, an adeno-associated virus serotype 1 vector expressing murine GALC under control of a chicken β-actin promoter (AAV1-GALC) was administered to newborn mice by unilateral intracerebroventricular injection. AAV1-GALC treatment significantly improved body weight gain and survival of the twitcher mice (n = 8) when compared with untreated controls (n = 5). The maximum weight gain after postnatal day 10 was significantly increased from 81% to 217%. The median lifespan was extended from 43 days to 78 days (range: 74–88 days) in the AAV1-GALC-treated group. Widespread expression of GALC protein and alleviation of KD neuropathology were detected in the CNS of the treated mice when examined at the moribund stage. Functionally, elevated levels of psychosine were completely normalized in the forebrain region of the treated mice. In the posterior region, which includes the mid- and the hindbrain, psychosine was reduced by an average of 77% (range: 53–93%) compared to the controls. Notably, psychosine levels in this region were inversely correlated with body weight and lifespan of AAV1-GALC-treated mice, suggesting that the degree of viral transduction of posterior brain regions following ventricular injection determined treatment efficacy on growth and survivability, respectively. Overall, our results suggest that viral vector delivery via the cerebroventricular system can partially correct psychosine accumulation in brain that leads to slower disease progression in KD.
SP11. Gene Expressions of Fgf7 and Postn in Canine Chordae Tendineae and Their Possible Relations to Tenogenesis in Chordae Tendineae and Potential Effects on Flexor Tenocyte Biology
Wan, Rou , Ren, Ye , Yu, Yinxian, Reisdorf, Ramona L., Moran, Steven L. , Zhao, Chunfeng , Gingery, Anne

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 21, 2023 | Volume: 11 | Issue: 5S | Pages: 126-126

10.1097/01.gox.0000938388.68998.93 Get It

16S rRNA Gene PCR/Sequencing of Heart Valves for Diagnosis of Infective Endocarditis in Routine Clinical Practice
Hong, Hyo‐Lim , Flurin, Laure , Greenwood‐Quaintance, Kerryl E. , Pritt, Bobbi S. , Norgan, Andrew P. , Patel, Robin , Wolf, Matthew J, Pritt, Bobbi S , Patel, Robin , Norgan, Andrew P , Wolf, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | July 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1128/jcm.00341-23 | PMID 37436146 Get It

Sequencing is increasingly used for infective endocarditis (IE) diagnosis. Here, the performance of 16S rRNA gene PCR/sequencing of heart valves utilized in routine clinical practice was compared with conventional IE diagnostics.
Detection of an MN1::ETV6 Gene Fusion in a Case of Acute Myeloid Leukemia with Erythroid Differentiation: A Case Report and Review of the Literature
Choate, Lauren A. , Jiang, Liuyan , Stein, Mariam I. , Shen, Wei , Peterson, Jess F , Shen, Wei , Baughn, Linda B. , Peterson, Jess F.

Mayo Clinic

Case Reports in Hematology | July 3, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-6

10.1155/2023/9771388 | PMID 37434656 Get It

The MN1::ETV6 gene fusion resulting from t(12;22)(p13;q12) has been rarely reported in myeloid neoplasms. We describe a 69-year-old male with newly diagnosed acute myeloid leukemia (AML) with erythroid differentiation and t(12;22)(p13;q12) demonstrated by conventional chromosome studies. Subsequent fluorescence in situ hybridization studies demonstrated a balanced ETV6 gene rearrangement (at 12p13). To further characterize this translocation, whole-genome sequencing was performed which confirmed t(12;22) with breakpoints involving the MN1 and ETV6 genes. Herein, we describe our case and review the literature to summarize the clinical and laboratory findings in patients with this rare but recurrent MN1::ETV6 gene fusion observed in myeloid neoplasms. Importantly, this case expands the clinical spectrum associated with the MN1::ETV6 gene fusion to include AML with erythroid differentiation. Lastly, this case demonstrates the importance of moving toward more comprehensive molecular testing to fully characterize the driver events in neoplastic genomes.
Incidental Detection of TFEB -Amplified Renal Cell Carcinoma by Colocated Gene Amplification of CCND3 (6p21): A Case Report and Review of the Literature
Repetto, Federico , Sirohi, Deepika , Greipp, Patricia T. , Mahlow, Jonathon , Greipp, Patricia T

Mayo Clinic

International Journal of Surgical Pathology | July 3, 2023 | Volume: 32 | Issue: 3 | Pages: 551-555

10.1177/10668969231185081 | PMID 37394760 Get It

TFEB-amplified renal cell carcinoma (RCC), which belongs to the MITF family of RCC, is characterized by genomic amplification at the 6p21.1 locus where the TFEB gene is located. The vascular endothelial growth factor A and cyclin D3 genes are also located at this same locus. When tumors lack classic morphologic features, they may be classified as “RCC not otherwise specified (NOS).” However, it is increasingly important to accurately diagnose the RCC subtype to define the patient's individual prognosis and select the subsequent therapeutic modalities, which now include targeted agents. Therefore, knowledge of the diagnostic features of TFEB-altered RCCs, such as t(6;11) RCCs and TFEB-amplified RCCs, is critical for identifying these tumors. Herein, we present an interesting case of TFEB-amplified RCC that was initially diagnosed as RCC NOS on biopsy of a renal tumor in a community practice setting with available molecular findings demonstrating CCND3 amplification. The genetic abnormality was “accidentally” detected due to the amplification of the colocated CCND3 gene at the 6p21 locus of the TFEB gene on a limited genetic sequencing panel. This case highlights the importance of molecular tests in accurately diagnosing RCC and carefully interpreting molecular findings in the context of histomorphologic features.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Gertz, Morie A. , Cohen, Adam D. , Comenzo, Raymond L. , Landau, Heather , Libby, Edward N., Liedtke, Michaela , Sanchorawala, Vaishali , Wechalekar, Ashutosh , Zonder, Jeffrey A. , Walling, Jackie , Guthrie, Spencer , Nie, Christie, Karp, Carol L. , Kinney, Gene G. , Kastritis, Efstathios , Landau, Heather , Liedtke, Michaela , Sanchorawala, Vaishali , Palladini, Giovanni , Merlini, Giampaolo , Gertz, Morie A , Cohen, Adam D , Kastritis, Efstathios , Schönland, Stefan , Wechalekar, Ashutosh D. , Palladini, Giovanni , Karp, Carol, Jin, Yuying, Merlini, Giampaolo

Mayo Clinic

Blood | June 27, 2023 | Volume: 142 | Issue: 14 | Pages: 1208-1218

10.1182/blood.2022019406 | PMID 37366170 Get It

Abstract Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited amyloid via macrophage-induced phagocytosis. VITAL was a phase 3 randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of birtamimab + standard of care (SOC) in 260 newly diagnosed, treatment-naive patients with AL amyloidosis. Patients received 24 mg/kg IV birtamimab + SOC or placebo + SOC every 28 days. The primary composite end point was the time to all-cause mortality (ACM) or centrally adjudicated cardiac hospitalization ≥91 days after the first study drug infusion. The trial was terminated early after an interim futility analysis; there was no significant difference in the primary composite end point (hazard ratio [HR], 0.826; 95% confidence interval [CI], 0.574-1.189; log-rank P = .303). A post hoc analysis of patients with Mayo stage IV AL amyloidosis, those at the highest risk of early mortality, showed significant improvement in the time to ACM with birtamimab at month 9 (HR, 0.413; 95% CI, 0.191-0.895; log-rank P = .021). At month 9, 74% of patients with Mayo stage IV AL amyloidosis treated with birtamimab and 49% of those given placebo survived. Overall, the rates of treatment-emergent adverse events (TEAEs) and serious TEAEs were generally similar between treatment arms. A confirmatory phase 3 randomized, double-blind, placebo-controlled clinical trial of birtamimab in patients with Mayo stage IV AL amyloidosis (AFFIRM-AL; NCT04973137) is currently enrolling. The VITAL trial was registered at www.clinicaltrials.gov as #NCT02312206.